Quick Asked: Theravance Biopharma Us Contact Us?
Last update: 27 Apr, 2024 
334 Views
What is theravance biopharma? Theravance Biopharma, Inc. ("Theravance Biopharma") is a persified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses.How can i watch the theravance biopharma conference call? A replay of the conference call will be available on Theravance Biopharma's website for 30 days through December 9, 2018. An audio replay will also be available through 8:00 pm ET on November 16, 2018 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and then entering confirmation code 3360289.What are the terms of the theravance biopharma mylan agreement? Under the terms of the agreement, Theravance Biopharma is leading the US development program for the revefenacin inhalation solution product, with all costs related to the registrational program reimbursed by Mylan up until the approval of the first new drug application, after which costs will be shared.
Listing Results Theravance Biopharma Us Contact Us? Question Answers
Theravance Biopharma to Present at Upcoming Investor
Morgan Stanley 18 th Annual Global Healthcare Conference 2020 on Monday, September 14 at 1:30 p.m. ET (10:30 a.m. PT / 5:30 p.m. GMT); H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 9:30 a.m. ET (6:30 a.m. PT / 1:30 p.m. GMT); Webcasts of the presentations may be accessed by visiting the "Investors" section ...
Jon Hinze Email, Phone Institutional Account Manager
Find Jon Hinze's accurate email address and contact/phone number in Adapt.io. Currently working as Institutional Account Manager at Theravance Biopharma in ...
Theravance Biopharma Inc, TBPH:NMQ summary FT.com
Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicin. es to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of
Theravance Biopharma, Inc. (TBPH) Stock Analysis
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD).
Theravance Biopharma, Inc. TBPH Stock Price & News
Theravance Biopharma, Inc. (TBPH) stock rallied over 1.78% intraday to trade at $10.88 a share on NASDAQ. The stock opened with a loss of -1.59% at $10.52 and touched an intraday high of $11.21, rising 4.86% against the last close of $10.69. ...